Multiple myeloma in the elderly: Clinical features and response to treatment in 113 patients

Haematologica

Volumn 81, Issue 3, 1996, Pages 238-244

  Clavio, Marino ^a   Casciaro, Salvatore ^c   Gatti, Anna Maria ^b   Spriano, Mauro ^c   Bonanni, Franco ^d   Poggi, Alessia ^c   Vallebella, Emanuela ^a   Pietrasanta, Daniela ^a   Prencipe, Emma ^b   Goretti, Riccardo ^d   Vimercati, Renato ^c   Rossi, Edoardo ^c   Masoudi, Bahman ^c   Ghio, Riccardo ^b   Boccaccio, Piero ^c   Ricciardi, Sandra ^d   Damasio, Eugenio ^c   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d SANTA CORONA HOSPITAL   (Italy)

Author keywords

Chemotherapy; Elderly; Multiple myeloma; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; MITOXANTRONE; PEPTICHEMIO; PREDNISONE; VINCRISTINE;

AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DRUG RESPONSE; ELDERLY CARE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA;

EID: 0030322032     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992; 2:225-48.
2. Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B-cell transcribing malignant plasma cell VDJ joined to Cμ sequence in immunoglobulin (IgG)- and IgA secreting multiple myelomas. J Exp Med 1993; 178:1091-6.
3. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688-93.
4. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor in human multiple myeloma. Br J Haematol 1990; 74:424-31.
5. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008-11.
6. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and β2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80:733-7.
7. Greipp PR, Lust JA, O'Fallon MO, et al. Plasma cell labeling index and β2-microglobulin predict survival independently of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81:3382-7.
8. Gobbi M, Cavo M, Savelli G, Baccarani M, Tura S. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone. Haematologica 1980; 65:437-45.
9. Osterborg A, Ahre A, Bjorkhölm M, et al. Alternating combination chemotherapy (VMPC/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III-A: randomized study from MGCS. Eur J Haematol 1989; 43:54-62.
10. Hjorth M, Hellquist L, Holmberg E, et al. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. Br J Haematol 1990; 74:185-91.
11. Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisolone even in high-risk patients. J Clin Oncol 1991; 9:444-8.
12. Cavagnaro F, Lein JM, Pavlovsky S, et al. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. Cancer Treat Rep 1980; 64:73-9.
13. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334-42.
14. Malpas JS, Bergsagel DE, Kyle RA. Myeloma biology and management. Chapter 11; Oxford Medical Publ., 1995.
15. Gobbi M, Cavo M, Tazzari PL, et al. Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. Eur J Haematol 1989; 43(Suppl 51):176-81.
16. Barlogie B, Gharton G. Bone marrow transplantation in multiple myeloma. Bone Marrow Transpl 1991; 7: 71-9.
17. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84:950-6.
18. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 84:4278-82.
19. Dimopoulos MA, Hester J, Huh Y, Champlin R, Alexanian R. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87:730-4.
20. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991; 325:1267-73.
21. Cohen HJ, Bartolucci A. Age and the treatment of multiple myeloma. Southeastern Cancer Study Group Experience. Am J Med 1985; 79:316-26.
22. Palva IP, Ahrenberg P, Ala-Harja K, et al. Treatment of multiple myeloma in old patients. Eur J Haematol 1989; 43:328-31.
23. Froom P, Quitt M, Aghai E. Multiple myeloma in the geriatric patient. Cancer 1990; 66:965-7.
24. Chronic Leukemia-Myeloma Task Force. National Cancer Institute. Proposed guidelines for protocol studies II: plasma cell myeloma. Cancer Chemother Rep 1973; 4:145-58.
25. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36:842-54.
26. Resegotti L. The therapy of hematological malignancies in the elderly. Haematologica 1993; 78:141-4.
27. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1:710-9.
28. Palmer M, Belch A, Brox L, Pollock E, Koch M. Are the current criteria for response useful in the management of multiple myeloma? J Clin Oncol 1987; 5:1373-7.
29. Marmont F, Levis A, Falda M, Resegotti L. Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone. Ann Oncol 1991; 2:191-5.
30. Bladè J, Lopez-Guillermo A, Bosch F, et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 1994; 88: 117-21.
31. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alpha-2 in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322:1430-4.
32. Browman GP, Rubin S, Walker I, et al. Interferon alpha 2b maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma: results of a randomized trial. Proc Am Soc Clin Oncol 1994; 13:408-15.